Questcor Pharmaceuticals Inc. (QCOR)
QCOR (NASDAQ:Drugs)
$37.34

+0.48
+1.30%
Today's Range: 36.76 - 37.97 |
QCOR Avg Daily Volume: 2,043,900
| Last Update: 05/17/13 - 4:00 PM EDT |
| Volume: 1,084,664 |
| YTD Performance: 37.95%
|
| Open: $37.07 |
| Previous Close: $36.86 |
| 52 Week Range: $17.25 -
$58.91 |
| Oustanding Shares: 59,554,145 |
| Market Cap: 2,195,165,785 |
6-Month Chart
TheStreet Ratings Grade for QCOR
| Buy |
Hold
|
Sell
|
| A+ |
A |
A- |
B+ |
B |
B- |
C+ |
C |
C- |
D+ |
D |
D- |
E+ |
E |
E- |
F |
Analysts Ratings
| Historical Rec |
Current |
1 Mo. Ago |
2 Mo. Ago |
3 Mo. Ago |
| Strong Buy |
6 |
6 |
6 |
5 |
| Moderate Buy |
0 |
0 |
0 |
0 |
| Hold |
2 |
1 |
1 |
2 |
| Moderate Sell |
0 |
0 |
0 |
0 |
| Strong Sell |
0 |
0 |
0 |
0 |
| Mean Rec. |
1.50 |
1.29 |
1.29 |
1.57 |
| Latest Dividend: |
0.25 |
| Latest Dividend Yield: |
2.71% |
| Dividend Ex-Date: |
04/18/13 |
| Price Earnings Ratio: |
11.48 |
|
| Price Earnings Comparisons: |
| QCOR |
Sector Avg. |
S&P 500 |
| 11.48 |
11.40 |
17.70 |
| Price Performance History (%Change): |
| 3 Mo |
1 Yr |
3 Y |
|
28.66%
|
-5.18%
|
302.84%
|
|
| GROWTH |
12 Mo |
3 Yr |
CAGR |
| Revenue |
133.40 |
4.77 |
0.78 |
| Net Income |
0.00 |
0.00 |
0.00 |
| EPS |
159.50 |
7.00 |
0.99 |
| Earnings for QCOR: |
| EBITDA |
0.30B |
| Revenue |
0.51B |
|
Average Earnings Estimates
;Qtr (09/13);FY (12/13);FY (12/14)&HEADING_LIST1=Qtr (06/12);Qtr (09/12);FY (12/12);FY (12/13)) |
|
| Average Estimate |
$1.13 |
$1.12 |
$4.06 |
$4.01 |
| Number of Analysts |
1 |
1 |
1 |
1 |
| High Estimate |
$1.13 |
$1.12 |
$4.06 |
$4.01 |
| Low Estimate |
$1.13 |
$1.12 |
$4.06 |
$4.01 |
| Prior Year |
$0.65 |
$0.92 |
$3.15 |
$4.06 |
| Growth Rate (Year over Year) |
73.85% |
21.74% |
28.89% |
-1.23% |
Feb 27, 2013 | 8:04 AM EST
Shares of QCOR now seen reaching $38, Jefferies said. Estimates also raised on Strong 4Q with robust 2013 outlook. Buy rating.
| Feb 22, 2013 | 11:00 AM EST
Martin Zweig had a colorful style and an insightful approach.
Feb 21, 2013 | 6:58 AM EST
QCOR was upgraded from Neutral to Buy, Mizuho said. $41 price target. Company should exceed consensus expectations in the near term.&nb...
Oct 09, 2012 | 8:40 AM EDT
Shares of QCOR upgraded to Buy from Hold, Jefferies said. $28 price target. Limited downside with improved visibility.
Sep 24, 2012 | 8:15 AM EDT
QCOR was downgraded to Market Perform, Leerink Swann said. Valuation call, following Aetna's Acthar decision.
| Sep 20, 2012 | 11:44 AM EDT
Disappointing earnings results have sent this name cascading lower.
Sep 20, 2012 | 8:20 AM EDT
Shares of QCOR now seen reaching $65, Oppenheimer said. Estimates also lowered on revision of Acthar coverage. Outperform rating.
Sep 20, 2012 | 8:15 AM EDT
Shares of QCOR downgraded to Hold from Buy, Jefferies said. $30 price target. Aetna policy change is explicit.
Sep 20, 2012 | 8:11 AM EDT
Shares of QCOR now seen reaching $45, according to Bank of America/Merrill Lynch. Estimates also reduced, following AET changes for Act...
| Sep 19, 2012 | 1:41 PM EDT
The worst case is priced in, and any positive news would send this one soaring.